Traditional ocular drug delivery methods suffer from low bioavailability, short precorneal residence time, and poor patient adherence due to ocular physiological and anatomical barriers. This review systematically summarizes biomaterial-based platforms for ocular drug delivery, focusing on controlled release, targeting, permeability, and synergistic therapy. The review also discusses key clinical features of ocular disorders, including dry eye disease, infectious keratitis, glaucoma, and age-related macular degeneration. It also evaluates the therapeutic performance and clinical translation of key systems, and identifies current challenges and future directions. This paper aims to provide theoretical foundations and innovative approaches for developing more efficient and safer ophthalmic drug delivery strategies.
Chen et al. (Mon,) studied this question.